Relocation of the production of pharmaceuticals: a strategic endeavour for the European Union

In recent years, there has been increasing concerns around drug supply shortages and discussions around the potential benefits of relocating medicine production back to the EU.

In recent years, there has been increasing concerns around drug supply shortages and discussions around the potential benefits of relocating medicine production back to the EU. With shortages of key antibiotics, anaesthetics and even paracetamol drug products, the COVID-19 pandemic has further highlighted Europe’s reliance on other markets for drug products, active pharmaceutical ingredients (API) and intermediates, particularly China. 

For this reason, many governmental and political leaders have reacted by encouraging companies to move drug production ‘back home’. In this article Recipharm’s Executive Vice President, Jean-Francois Hilaire article explores how pharmaceutical supply chains are structured and to what extent production could be repatriated into Europe, providing that some roadblocks are removed.

He also shares insight on why Europe may well be the perfect choice for certain API and drug product development and manufacturing.

You can read more here, on page 60 onwards.